{"nctId":"NCT00800683","briefTitle":"Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive","startDateStruct":{"date":"2008-12"},"conditions":["Diabetes Mellitus, Type 2"],"count":133,"armGroups":[{"label":"BI 1356","type":"EXPERIMENTAL","interventionNames":["Drug: BI 1356"]},{"label":"placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"BI 1356","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Male and female patients with type 2 diabetes and with glomerular filtration rate (GFR) \\<30 ml/min, who are not on chronic dialysis.\n* Insufficient glycemic control (hemoglobin A1c (HbA1c) between 7.0% and 10.0%)\n* Age 18 or over and not older than 80 years\n\nExclusion criteria:\n\n* Treatment with any other anti diabetic drug other than insulin and/or sulphonylurea within 3 months prior to informed consent\n* Myocardial infarction, stroke or transient ischemic attack (TIA) within 6 months prior to informed consent\n* Unstable or acute congestive heart failure","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"HbA1c Change From Baseline at Week 12","description":"HbA1c is measured as a Percent. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline continuous HbA1c , creatinine clearance at baseline and previous anti-diabetic medication.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.15","spread":"0.15"},{"groupId":"OG001","value":"-0.76","spread":"0.14"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change From Baseline at Week 52","description":"HbA1c is measured as a Percent. Thus, this change from baseline reflects the Week 52 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for continuous baseline HbA1c , creatinine clearance at baseline and previous anti-diabetic medication.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.16"},{"groupId":"OG001","value":"-0.71","spread":"0.15"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change From Baseline at Week 18","description":"HbA1c is measured as a Percent. Thus, this change from baseline reflects the Week 18 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for continuous baseline HbA1c , creatinine clearance at baseline and previous anti-diabetic medication.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.14"},{"groupId":"OG001","value":"-0.57","spread":"0.14"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change From Baseline at Week 24","description":"HbA1c is measured as a Percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for continuous baseline HbA1c , creatinine clearance at baseline and previous anti-diabetic medication.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.14"},{"groupId":"OG001","value":"-0.64","spread":"0.13"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change From Baseline at Week 30","description":"HbA1c is measured as a Percent. Thus, this change from baseline reflects the Week 30 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for continuous baseline HbA1c , creatinine clearance at baseline and previous anti-diabetic medication.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.16"},{"groupId":"OG001","value":"-0.67","spread":"0.16"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change From Baseline at Week 36","description":"HbA1c is measured as a Percent. Thus, this change from baseline reflects the Week 36 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for continuous baseline HbA1c , creatinine clearance at baseline and previous anti-diabetic medication.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.16"},{"groupId":"OG001","value":"-0.72","spread":"0.15"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change From Baseline at Week 42","description":"HbA1c is measured as a Percent. Thus, this change from baseline reflects the Week 42 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for continuous baseline HbA1c , creatinine clearance at baseline and previous anti-diabetic medication.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.16"},{"groupId":"OG001","value":"-0.73","spread":"0.15"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change From Baseline at Week 48","description":"HbA1c is measured as a Percent. Thus, this change from baseline reflects the Week 48 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for continuous baseline HbA1c , creatinine clearance at baseline and previous anti-diabetic medication.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"0.15"},{"groupId":"OG001","value":"-0.77","spread":"0.14"}]}]}]},{"type":"SECONDARY","title":"The Occurrence of Treat to Target Efficacy Response, That is an HbA1c Under Treatment of <6.5% After 52 Weeks of Treatment","description":"The percentage of patients with an HbA1c value below 6.5% at week 52 was calculated for each treatment arm. Non-completers were imputed as failure (NCF). Analysis was only performed on patients with baseline HbA1c\\>=6.5%","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"6.1","spread":null}]}]}]},{"type":"SECONDARY","title":"The Occurrence of a Treat to Target Efficacy Response, That is an HbA1c Under Treatment of <7.0% After 52 Weeks of Treatment","description":"The percentage of patients with an HbA1c value below 7.0% at week 52 was calculated for each treatment arm. Non-completers were imputed as failure (NCF). Analysis was only performed on patients with baseline HbA1c\\>=7%.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":null},{"groupId":"OG001","value":"18.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c Lowering by 0.5% at Week 52","description":"The percentage of patients with an HbA1c reduction from baseline \\>=0.5% at week 52 was calculated for each treatment arm. Non-completers were imputed as failure (NCF).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":null},{"groupId":"OG001","value":"27.3","spread":null}]}]}]},{"type":"SECONDARY","title":"FPG Change From Baseline at Week 12","description":"This change from baseline reflects the week 12 FPG minus the baseline FPG. Means are treatment adjusted for continuous baseline FPG , creatinine clearance , HbA1c and background of anti diabetic drugs","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.08","spread":"11.08"},{"groupId":"OG001","value":"-8.81","spread":"10.66"}]}]}]},{"type":"SECONDARY","title":"FPG Change From Baseline at Week 18","description":"Model includes treatment, continuous baseline FPG , creatinine clearance , HbA1c and background of anti diabetic drugs","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.72","spread":"7.94"},{"groupId":"OG001","value":"-14.97","spread":"7.64"}]}]}]},{"type":"SECONDARY","title":"FPG Change From Baseline at Week 24","description":"This change from baseline reflects the week 24 FPG minus the baseline FPG. Means are treatment adjusted for continuous baseline FPG , baseline creatinine clearance , baseline HbA1c and background of anti diabetic drugs","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.22","spread":"7.84"},{"groupId":"OG001","value":"-16.93","spread":"7.54"}]}]}]},{"type":"SECONDARY","title":"FPG Change From Baseline at Week 30","description":"This change from baseline reflects the week 30 FPG minus the baseline FPG. Means are treatment adjusted for continuous baseline FPG , baseline creatinine clearance , baseline HbA1c and background of anti diabetic drugs","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.54","spread":"7.68"},{"groupId":"OG001","value":"-10.12","spread":"7.39"}]}]}]},{"type":"SECONDARY","title":"FPG Change From Baseline at Week 36","description":"This change from baseline reflects the week 36 FPG minus the baseline FPG. Means are treatment adjusted for continuous baseline FPG , baseline creatinine clearance , baseline HbA1c and background of anti diabetic drugs","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.29","spread":"8.53"},{"groupId":"OG001","value":"-20.53","spread":"8.20"}]}]}]},{"type":"SECONDARY","title":"FPG Change From Baseline at Week 42","description":"This change from baseline reflects the week 42 FPG minus the baseline FPG. Means are treatment adjusted for continuous baseline FPG , baseline creatinine clearance , baseline HbA1c and background of anti diabetic drugs","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.25","spread":"8.02"},{"groupId":"OG001","value":"-8.88","spread":"7.71"}]}]}]},{"type":"SECONDARY","title":"FPG Change From Baseline at Week 48","description":"This change from baseline reflects the week 48 FPG minus the baseline FPG. Means are treatment adjusted for continuous baseline FPG , baseline creatinine clearance , baseline HbA1c and background of anti diabetic drugs","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.52","spread":"8.26"},{"groupId":"OG001","value":"-3.45","spread":"7.95"}]}]}]},{"type":"SECONDARY","title":"FPG Change From Baseline at week52","description":"This change from baseline reflects the week 52 FPG minus the baseline FPG. Means are treatment adjusted for continuous baseline FPG , baseline creatinine clearance , baseline HbA1c and background of anti diabetic drugs","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.81","spread":"7.92"},{"groupId":"OG001","value":"-5.47","spread":"7.62"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Antidiabetic Background Therapy Dose at 52 Weeks Compared to Baseline and Over Time","description":"Number of patients with at least one change in daily dose, determined by at least a 10% increase in insulin.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinically Relevant Drug-related Abnormalities for Blood Chemistry, Pulse Rate, Laboratory Parameters and ECG","description":"Clinically relevant drug-related abnormalities for blood chemistry, pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as adverse events.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":27,"n":65},"commonTop":["Hypoglycaemia","Hyperglycaemia","Hyperkalaemia","Diarrhoea","Oedema peripheral"]}}}